Sepsis, a life-threatening organ dysfunction caused by a dysregulated host response, leads the U.S in both mortality rate and cost of treatment. Sepsis treatment protocols currently rely on broad and non-specific parameters like heart and respiration rate, and temperature; however, studies show that biomarkers Interlukin-6 (IL-6) and Procalcitonin (PCT) correlate to sepsis progression and response to treatment. Prior work also suggests that using multi-parameter predictive analytics with biomarkers and clinical information can inform treatment to improve outcome. A point-of-care (POC) platform that provides information for multiple biomarkers can aid in the diagnosis and prognosis of potentially septic patients. Using impedance cytometry, microbead immunoassays, and biotin-streptavidin binding, we report a microfluidic POC system that correlates microbead capture to IL-6 and PCT concentrations. A multiplexed microbead immunoassay is developed and validated for simultaneous detection of both IL-6 and PCT from human plasma samples. Using the POC platform, we quantified plasma samples containing healthy, medium (~10³pg/ml) and high (~10⁵pg/ml) IL-6 and PCT concentrations with various levels of significance (P < 0.05-P < 0.00001) and validated the concept of this device as a POC platform for sepsis biomarkers.

中文翻译：

---

使用微流控生物芯片平台同时电检测IL-6和PCT。

败血症是由宿主反应失调引起的威胁生命的器官功能障碍，在死亡率和治疗费用上均领先于美国。脓毒症治疗方案目前依赖于广泛的和非特异性的参数，例如心脏和呼吸频率以及温度。然而，研究表明，生物标志物白细胞介素6（IL-6）和降钙素原（PCT）与败血症的进展和对治疗的反应相关。先前的工作还表明，将多参数预测分析与生物标志物和临床信息一起使用可以为治疗提供信息，以改善疗效。为多种生物标志物提供信息的即时护理（POC）平台可以帮助潜在败血症患者的诊断和预后。使用阻抗细胞仪，微珠免疫分析和生物素-链霉亲和素结合，我们报告了一种微流体POC系统，该系统将微珠捕获与IL-6和PCT浓度相关联。开发并验证了用于从人血浆样品中同时检测IL-6和PCT的多重微珠免疫测定法。使用POC平台，我们对包含健康，中等（〜10个IL-6和PCT浓度高（³ pg / ml）和高浓度（〜10 ⁵ pg / ml）的IL-6和PCT（P  <0.05- P <  0.00001），并验证了该设备作为脓毒症生物标记物POC平台的概念。